Labiotech.eu

Interview 9 May 2017

Video Interview: Meet the Oxford COO improving Tech Transfer

Adam Stoten is the new COO of Oxford University Innovation. Philip caught up with him at BioTrinity in London to talk about tech transfer. Both from academic and industrial perspectives, tech transfer has a reputation for being an onerous process. But some organizations are working steadfastly to streamline it with great success, like Oxford University Innovation. […]

May 9, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 9 May 2017

AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal

As part of the deal with Sanofi, Exscientia will tackle the discovery and design of new bispecific drugs using artificial intelligence algorithms. Exscientia, based in Scotland, is a company that uses artificial intelligence (AI) to develop new drugs faster. Its edge-cutting technology has caught the attention of Sanofi, which is offering Exscientia research funding and […]

May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

GammaDelta Therapeutics Takeda Collaboration 1

More News! 9 May 2017

British Biotech Startup Partners with Takeda to Advance its T Cell Platform

GammaDelta Therapeutics and Takeda have formed a strategic collaboration to develop a novel T cell platform, which is based on gamma delta (γδ) T cells. Based in London, GammaDelta Therapeutics builds on the work of Adrian Hayday and Oliver Nussbaumer of Kings College London and The Francis Crick Institute. Backed by the huge British VC […]

May 9, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 9 May 2017

Scottish Shark Antibodies have caught Amgen’s Eye

Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest naturally-occurring antibody binding domains. “They are remarkably stable,” Caroline Barelle told me this morning at BioTrinity in London. “They can survive extreme pH and temperatures […]

May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

hypermutation biofuels antimicrobial resistance cancer

News and Trends 9 May 2017

Hypermutation could be the Key to Biofuels – and Antibiotic Resistance

Instead of taking a spa vacation, stressed out bacteria start mutating their DNA fast. This nearly suicidal behavior can yield a lucky survivor in nature. For us, it could mean new strategies for biofuel production and fighting antibiotic resistance, researchers say. Researchers from the Centre of Microbial and Plant Genetics at KU Leuven, in Belgium, are shining […]

May 9, 2017 - 2 minutesmins - By Denise Neves Gameiro

In Depth 9 May 2017

Rise of the Superbugs: How is Biotech Fighting Antibiotic Resistance?

Fewer antibiotics are produced as development costs rise. We reached out to a few companies addressing the serious issue of antibiotic resistance. Antibiotic resistance is one of the greatest threats to our societies and health systems, and the number of antibiotic-resistant bacteria is growing at a disquieting rate. The estimated number of people killed by […]

May 9, 2017 - 8 minutesmins - By External Contributor

News and Trends 8 May 2017

The EU Approves New Treatment for a Rare Pediatric Cancer

Update (08/05/2017): The European Commission has granted marketing authorization to Apeiron Biologic’s APN311 in the rare pediatric cancer neuroblastoma. Originally published on 27/03/2017 Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high-risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches to treat cancer. […]

May 8, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

Teva and Active Biotech have failed Phase III with their Multiple Sclerosis drug laquinimod to treat the relapsing-remitting form of the disease. Teva and Active Biotech have faced another setback with their long-expected successor to Teva’s Copaxone, laquinimod, for the treatment of Multiple Sclerosis (MS). The drug failed to meet the primary endpoint, trying to improve the […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

French Researchers Discover a Target to Prevent Zika Birth Defects

Researchers from the Institut Pasteur and the Inserm have identified a protein target that, when overexpressed, can block Zika infections. The recent Zika epidemics in the Pacific and South America has led the World Health Organization (WHO) to declare a state of global emergency. One of the biggest concerns at the moment is that the […]

May 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Immunocore GSK Immuno oncology collaboration

News and Trends 8 May 2017

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

Seuss Consulting CRO Sponsor partnerhsip

News and Trends 8 May 2017

Top 5 Mistakes that Will Doom a CRO-Supplier Partnership Before it Starts

A healthy relationship between a trial sponsor and the CRO or supplier can be the key to success – here is a list of how to address the biggest challenges. By 2020, 72% of clinical trials are projected to be outsourced to contract research organizations (CROs), compared to just 23% in 2012. The main reason […]

May 8, 2017 - 7 minutesmins - By External Contributor

Interview 8 May 2017

Meet the co-developer of the first commercial mAb and gene therapy

Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the first commercial monoclonal antibody, Remicade, and the first market-approved gene therapy, Glybera. I was curious to know what he did to achieve such an impressive track record. Sander van Deventer was trained as an internist […]

May 8, 2017 - 5 minutesmins - By Philip Hemme

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Video Interview: Meet the Oxford COO improving Tech Transfer

AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal

British Biotech Startup Partners with Takeda to Advance its T Cell Platform

Scottish Shark Antibodies have caught Amgen’s Eye

Hypermutation could be the Key to Biofuels – and Antibiotic Resistance

Rise of the Superbugs: How is Biotech Fighting Antibiotic Resistance?

The EU Approves New Treatment for a Rare Pediatric Cancer

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

French Researchers Discover a Target to Prevent Zika Birth Defects

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Top 5 Mistakes that Will Doom a CRO-Supplier Partnership Before it Starts

Meet the co-developer of the first commercial mAb and gene therapy

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!